Orchestra BioMed Holdings, Inc. has announced a public offering of 15 million shares of its common stock, aiming to raise approximately $75 million. This move is significant as it reflects the company’s strategy to enhance its financial standing and support its growth initiatives in the competitive surgical and medical instruments sector.
The offering is set to be executed through underwriters including Piper Sandler and TD Cowen, with a public offering price of $5.00 per share. The last reported sale price of the company’s common stock on November 5, 2026, was $5.62 per share, indicating a slight discount to attract investors.
Background
Orchestra BioMed Holdings, Inc. is a company incorporated in Delaware, primarily engaged in the development of innovative surgical and medical instruments and apparatus. The company trades on the Nasdaq under the ticker symbol “OBIO.” Recent filings indicate that it is classified under the SIC code 3841, which pertains to surgical and medical instruments and apparatus. The company has been active in the market, with multiple filings in recent days, including a previous prospectus supplement.
What the Filing Says
According to the filing dated November 6, 2026, “We are offering 15,000,000 shares of our common stock pursuant to this prospectus supplement and the accompanying base prospectus.” The filing also outlines that the underwriters have an option to purchase an additional 2,250,000 shares, which could increase the total proceeds to approximately $81 million if fully exercised.
Impact
This offering may affect various stakeholders, including current shareholders and potential investors. For current shareholders, the dilution of shares could impact their ownership percentage, while potential investors may view this as an opportunity to invest in a growing company within the surgical and medical instruments sector.
What's Next
The underwriters expect to deliver the shares against payment in New York on or about November 9, 2026. Further details regarding the use of proceeds from this offering are likely to be disclosed in subsequent filings.
Read Next
Q/C Technologies Enters Omnibus Amendment Agreement
ONE Nuclear Energy settles consulting fees with stock issuance
HCW Biologics delays stockholder vote amid quorum issues
bioAffinity Technologies amends share structure in 8-K filing
VisionWave amends sponsorship deal with Hen Basketball Haifa Club
Apimeds Pharmaceuticals Amends Agreement with FreeT Inc.










